Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
366 active trials6 approved drugs33 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,281 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT03768531 | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Apr 13, 2020 | clinicaltrials |
| NCT00948935 | Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma | completed | Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT02456714 | Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma(4CC) | completed | Phase 2 | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04300959 | Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT03873532 | A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients | unknown | Phase 2 / Phase 3 | 298 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00779454 | Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma | completed | Phase 2 | 72 | Vejle HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT03818997 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer(DYNAMIC) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT02496741 | Metformin And Chloroquine in IDH1/2-mutated Solid Tumors(MACIST) | completed | Phase 1 / Phase 2 | 15 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT04156958 | Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma(FSTAMBTA) | unknown | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT04111380 | Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers | unknown | Phase 2 | 30 | Henan Provincial People's HospitalOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02773459 | MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer | completed | Phase 1 / Phase 2 | 31 | Seoul National University HospitalOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT04077983 | Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 4, 2019 | clinicaltrials |
| NCT03042182 | Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma(cholangio) | unknown | Phase 1 / Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Aug 30, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT02425137 | A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer | completed | Phase 2 | 51 | TTY BiopharmINDUSTRY | 1 | Aug 21, 2019 | clinicaltrials |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT02108145 | Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 70 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT04027764 | Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer | unknown | Phase 2 | 30 | Dai, GuanghaiOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT03185988 | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | unknown | Phase 2 | 100 | Shen LinOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02955771 | Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma | terminated | Phase 2 | 7 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 17, 2019 | clinicaltrials |
| NCT04004234 | A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC | unknown | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT02350686 | XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy | unknown | Phase 2 | 67 | Samsung Medical CenterOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT01766219 | CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 17 | Wake Forest University Health SciencesOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT02966821 | Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | completed | Phase 2 | 39 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT01821248 | A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis | unknown | Phase 2 | 25 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | Feb 21, 2019 | clinicaltrials |
| NCT01917617 | Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer | completed | Phase 2 | 50 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | Feb 21, 2019 | clinicaltrials |
| NCT02053376 | A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy | completed | Phase 2 | 43 | Nathan Bahary, MDOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | suspended | Phase 2 | 25 | Shi MingOTHER | 1 | Jan 28, 2019 | clinicaltrials |
| NCT03772132 | Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | unknown | Phase 2 | 100 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT03768375 | Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | unknown | Phase 2 | 150 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer | terminated | Phase 2 | 29 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03702491 | Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma | unknown | Phase 2 | 138 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT02181634 | Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma(PrE0204) | completed | Phase 2 | 74 | PrECOG, LLC.OTHER | 2 | Oct 3, 2018 | clinicaltrials |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | terminated | Phase 2 | 6 | Allina Health SystemOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT02433639 | Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer | completed | Phase 2 | 24 | Seoul National University HospitalOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT03633773 | Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | Phase 1 / Phase 2 | 9 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT01534637 | Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer | completed | Phase 2 | 22 | Wake Forest University Health SciencesOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | terminated | Phase 2 | 33 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT02609958 | ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy | completed | Phase 2 | 32 | ASLAN PharmaceuticalsOTHER | 3 | May 29, 2018 | clinicaltrials |
| NCT01815307 | Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer | completed | Phase 2 | 70 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | May 16, 2018 | clinicaltrials |
| NCT01912053 | Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma(MispheC) | completed | Phase 2 | 41 | Center Eugene MarquisOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT03521219 | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT02836847 | Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | unknown | Phase 2 | 152 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 7, 2018 | clinicaltrials |
| NCT00142480 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00101036 | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2018 | clinicaltrials |
| NCT00789958 | S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct | completed | Phase 2 | 105 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 9, 2018 | clinicaltrials |
| NCT02374489 | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma | terminated | Phase 2 | 9 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 5, 2018 | clinicaltrials |
Data updated 23 days agoSource updated May 21, 2020source: clinicaltrials